Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cornell University | OTHER |
Not provided
Not provided
Not provided
Not provided
Healthcare workers and COVID-19 patients may experience psychological distress consequent to the pandemic, and are at particularly elevated risk for experiencing posttraumatic stress disorder (PTSD), based on evidence from previous infectious disease outbreaks. The best-validated treatment for PTSD is exposure therapy. Exposure therapy help patients suffering from PTSD to revisit and overcome their traumatic experiences. Including virtual reality in exposure therapy has a long history in treating PTSD; and has been used to treat military veterans and first-responders following 9/11. The investigators are developing and testing a virtual environment to treat PTSD including sub threshold PTSD symptoms in HCWs who experience occupational related trauma (e.g., working with COVID-19 patients) and COVID-19 patients. An independent evaluator will assess symptoms of PTSD and other psychopathology, using structured clinical interviews and self-report measures with well-established psychometric properties, at baseline, halfway through treatment, after completion of treatment, and at three-months post-treatment. Participants will complete ten ninety minute sessions (in-person or remotely), twice a week for five weeks aimed at mitigating their symptoms of PTSD. Remote participants will receive VR headsets after the baseline assessment and will keep them for the duration of the study. The pilot study will aim to demonstrate the feasibility and the tolerability of the virtual reality intervention in these populations.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Virtual Reality Exposure Therapy | Experimental | Virtual Reality Exposure Therapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Virtual Reality Exposure Therapy | Behavioral | Ten ninety minute sessions of Virtual Reality Exposure Therapy twice a week for five weeks, either remotely or in person. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Clinician Administered PTSD Score (CAPS-V) | Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-V) Score. Total Scores range from 0-80. Higher scores indicate greater symptom severity. | Baseline to approximately five weeks |
| Feasibility Indicator: Recruitment | Feasibility assessment will include recruitment defined as number of individuals interested in the intervention. | Baseline |
| Feasibility Indicator: Enrollment | Feasibility assessment will include enrollment defined as number of participants signing the informed consent form. | Baseline |
| Feasibility Indicator: Retention | Feasibility assessment will include retention defined as the number of participants completing the full intervention. | Post-Treatment Assessment at approximately 5 weeks |
| Acceptability Indicator: Satisfaction | Acceptability and treatment satisfaction will be rated with a Likert scale. | Post-Treatment Assessment at approximately 5 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Anxiety Symptoms measured by the Generalized Anxiety Disorder 7-Item Scale | Scored between 0-21: Cut offs: 0-4 = None 5-9 = Mild anxiety 10-14 = Moderate anxiety 15-21 = Severe anxiety Higher scores indicate greater symptom severity. | Baseline to approximately five weeks |
| Change in Depressive Symptoms measured by the Quick Inventory of Depressive Symptomatology |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Isabelle McLeod Daphnis, BS | Contact | 3108256016 | sum4009@med.cornell.edu |
| Name | Affiliation | Role |
|---|---|---|
| JoAnn Difede, PhD | Weill Medical College of Cornell University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Weill Cornell Medicine | Recruiting | New York | New York | 10065 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013313 | Stress Disorders, Post-Traumatic |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
| D001523 | Mental Disorders |
| D011024 | Pneumonia, Viral |
Not provided
Not provided
| ID | Term |
|---|---|
| D063367 | Virtual Reality Exposure Therapy |
| ID | Term |
|---|---|
| D003887 | Desensitization, Psychologic |
| D001521 | Behavior Therapy |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
16-item self-report measure. Scored between 0-27. Higher scores indicate greater symptom severity. |
| Baseline to approximately five weeks |
| Change in score on the Insomnia Sleep Index | 7 item self-report measure. Total scores range from 0-28, with higher scores indicating higher insomnia severity. | Baseline to approximately five weeks |
| Change in score on the PTSD Checklist for DSM-5 (PCL-5) | The well-validated PCL-5 will assess self-reported PTSD symptom severity. Scores range from 0-80. Higher scores indicate greater symptom severity. | Baseline to approximately five weeks |
| Change in Score on the Occupational Stress Inventory Revised (OSI-R) | The scale is comprised of 140 items total. The measure is comprised of 14 different scales and respondents indicate on a 5-point scale the frequency of a stress-related event. | Baseline to approximately five weeks |
| Change in score on the Modified Moral Injury Events Scale | 11 item self-report measure that measures moral injury. Statements related to distress or feelings of betrayal related to potentially morally injurious events are rated on a 6 point scale ranging from 1 (strongly agree) to 6 (strongly disagree). Score range is 11-66, with higher scores reflecting greater moral injury. | Baseline to approximately five weeks |
| Change in score on the Sheehan Disability Scale (SDS) | 10 point visual analog scale to rate the extent to which work/school, social life and home life or family responsibilities are impaired by his or her symptoms. The 3 items can be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). | Baseline to approximately five weeks |
| Change in score on the Social Adjustment Scale (SAS) | Subjects rate their own social functioning over times on a 5-point scale on items covering work for pay, housework, extended family, parenting, marital status, social activity and leisure, family unit and student status (sub-scales). Mean values of all the sub-scales are used, with a range from 0-5. Higher score = worse outcome. | Baseline to approximately five weeks |
| Change in score on the Moral Distress Scale | 21 item self-report measure measuring moral distress (the emotional state that arises from a situation when an individual feels that the ethically correct action to take is different from what he/she is tasked with doing). Score range is 0-336. Higher scores indicate greater moral distress. | Baseline to approximately five weeks |
| Change in score on the Quality of Life Inventory | The assessment yields an overall score and profile in 16 areas of life; health, self-esteem, goals and values, money, work, play, learning, creativity, helping, love, friends, children, relatives, home, neighbourhood, and community. Higher scores indicate higher level of quality of life. | Baseline to approximately five weeks |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |